5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence

    October 2020 in “ Bladder cancer ”
    Yoshika Nagata, T. Goto, Guiyang Jiang, Yuki Teramoto, Hiroshi Miyamoto
    Image of study
    TLDR 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
    The document from December 14, 2020, presents findings from an in vitro study which determined that 5α-reductase inhibitors (5α-RIs) such as dutasteride, finasteride, and epristeride do not prevent the development or progression of urothelial cancer. The study used a human non-neoplastic urothelial cell line and human bladder cancer lines to assess the effects of these drugs. While the androgen receptor antagonist bicalutamide significantly inhibited the proliferation of AR-positive bladder cancer cells, the 5α-RIs did not have a significant effect on inhibiting cell migration or the neoplastic transformation of cells treated with testosterone. The conclusion drawn was that 5α-RIs, even at high doses, do not impact the prevention of tumorigenesis or tumor progression in urothelial cancer.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Community Posts Join

    6 / 91 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 1 year ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

      community DHT/Testosterone levels in scalp Fin VS Dut.

      in Finasteride/Dutasteride  60 upvotes 5 months ago
      Dutasteride raises scalp testosterone by 99%, which may not be ideal for those sensitive to all androgens. Some argue finasteride's balancing act might be better, while others believe dutasteride is superior for hair regrowth.

      community How is my hair loss stack looking?

      in Finasteride/Dutasteride  178 upvotes 5 months ago
      The user is using finasteride, dutasteride, Nizoral, biotin, RU58841, minoxidil, Pantostin/Alfatradiol, Stemoxydine, and micro needling for hair loss. They are considering adding oral minoxidil.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

    Related Research

    4 / 4 results